Drugs / LINRODOSTAT
LINRODOSTAT
also known as
BMS-986205 · BMS-986205 MESYLATE · BMS-986205 METHANESULFONATE · BMS-986205-04 · F 001287 · LINRODOSTAT MESYLATE · ONO 7701
Small molecule targets IDO1 via inhibition
Trials 24
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 110 trials · 1 met primary | ||||||
| Phase 1 | NCT04047706 | Aug 2019 → Feb 2027 expected | glioblastoma | Northwestern University | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03936374 | May → Jul 2019 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT03335540 | May 2018 → Mar 2021 | cancer of unknown primary site | Bristol-Myers Squibb | Completed | Met primary |
| Phase 1 | NCT03374228 | Jan → Feb 2018 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT03378310 | Dec 2017 → Feb 2018 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT03346837 | Nov → Dec 2017 | cancer | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT03362411 | Nov 2017 → Feb 2018 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT03312426 | Oct → Nov 2017 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT03247283 | Jul → Oct 2017 | cancer | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT03192943 | Jun 2017 → Dec 2018 | cancer of unknown primary site | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT03792750 | Dec 2018 → Dec 2020 | cancer of unknown primary site | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1/2 | NCT03695250 | Oct 2018 → Nov 2020 | hepatocellular carcinoma | Edward Kim | Terminated | No outcome recorded Stop: Business |
| Phase 1/2 | NCT03459222 | May 2018 → Feb 2025 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1/2 | NCT02658890 | Apr 2016 → Oct 2021 | melanoma, non-small cell lung carcinoma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 27 trials | ||||||
| Phase 2 | NCT04106414 | Sep 2019 → Sep 2026 overdue | endometrium adenocarcinoma, uterine carcinosarcoma | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04007588 | Sep → Dec 2019 | metastatic melanoma | Dana-Farber Cancer Institute | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT03854032 | Apr 2019 → Dec 2025 overdue | disorder of pharynx, laryngeal disorder, oral cavity squamous cell carcinoma | Thomas Jefferson University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03519256 | Aug 2018 → Aug 2022 | urinary bladder cancer | Bristol-Myers Squibb | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT02996110 | Feb 2017 → Nov 2021 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2 | NCT02935634 | Nov 2016 → May 2022 | gastric cancer | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2 | NCT02750514 | May 2016 → Jan 2020 | cancer of unknown primary site | Bristol-Myers Squibb | Terminated | No outcome recorded Stop: Enrollment |
| Phase 33 trials | ||||||
| Phase 3 | NCT03417037 | May 2018 → Apr 2021 | non-small cell lung carcinoma | Bristol-Myers Squibb | Withdrawn | No outcome recorded Stop: Business |
| Phase 3 | NCT03386838 | Mar → Apr 2018 | head and neck cancer | Bristol-Myers Squibb | Withdrawn | No outcome recorded Stop: Business |
| Phase 3 | NCT03329846 | Nov 2017 → Jul 2020 | melanoma, skin cancer | Bristol-Myers Squibb | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2017-11-10 | Bristol-Myers Squibb | Results Encouraging Response Observed with Opdivo (nivolumab) Plus Investigational IDO1 Inhibitor, BMS-986205, in Heavily Pre-Treated Patients with Advanced Cancers in Phase 1/2a Study CA017-003 bms.com ↗
In the bladder cancer cohort, the objective response rate (ORR) and disease control rate (DCR) were 32% and 44%, respectively. |
| 2017-03-01 | Bristol-Myers Squibb | Results Bristol-Myers Squibb to Present Data That Advances Understanding of Effects of Immuno-Oncology Therapies on Cancer Biology and Patient Outcomes at AACR 2017 bms.com ↗
BMS-986205, an optimized indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, is well tolerated with potent pharmacodynamic activity, alone and in combination with nivolumab in advanced cancers in a phase 1/2a trial |
All press releases naming this drug 2 releases
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 25 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LINRODOSTAT | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297598 ↗ |
| Known as | BMS-986205 | “BMS-986205 100 mg every 4 weeks.” NCT04106414 ↗ |
| Known as | BMS-986205 MESYLATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297598 ↗ |
| Known as | BMS-986205 METHANESULFONATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297598 ↗ |
| Known as | BMS-986205-04 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297598 ↗ |
| Known as | F 001287 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297598 ↗ |
| Known as | LINRODOSTAT MESYLATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297598 ↗ |
| Known as | ONO 7701 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297598 ↗ |
| Action | Inhibit | “IDO1 Inhibitor” NCT03459222 ↗ |
| Modality | Small molecule | — CHEMBL4297598 ↗ |
| Route | Oral | “Single Oral Dose of BMS-986205” NCT03247283 ↗ |
| Target | IDO1 | “BMS-986205 (IDO1 Inhibitor)” NCT03459222 ↗ |